Key Drivers
- Persistent Losses
- Declining Liquidity
- Rising Leverage
AIAI Summary
KOD is a high-risk, catalyst-driven biotech where Phase 3 success—especially KSI-501 superiority versus aflibercept—could unlock substantial upside, but investors should limit exposure until data or partnering improves confidence that its rapidly declining cash balance will not force punitive dilution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Persistent Losses
- •Declining Liquidity
- •Rising Leverage
KOD faces high financial risk from persistent losses, heavy cash burn, declining liquidity, rising leverage, and no reported revenue to support its elevated valuation.
Price Behavior
Key Price Behavior Insights:
- •Lower-high trend
- •Key support
- •Recovery trigger
KOD is bearish after an 18% decline over the last month, with $32.71 support and a recovery above $33.78–$35.36 needed to improve the outlook.
Sharp 18% decline over the last month
Sentiment & News
Key News Insights:
- •Stake Increase
- •Catalyst Potential
- •Event-Driven Risk
Algert Global increased its Kodiak Sciences stake by 26.1%, signaling institutional interest ahead of potentially catalyst-driven biotech events.
Increased institutional buying may support sentiment, but KOD remains highly dependent on clinical and regulatory developments
Similar Companies in Healthcare
Other companies in the same sector with AI ratings